According to 2013 WHO report, there are inadequacies in TB case management for multi-drug resistant TB (MDR-TB)—notably, gaps between the number of cases detected and the number of patients started on second-line TB treatment. In Uganda, a survey conducted in 2010 estimated the prevalence of MDR-TB at 12.1% among previously treated patients and a 1.3% among new patients. But why are there emerging cases of DR-TB?